The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first results
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Jochen G Mainz und 10 weiteren Autor:innen. Beteiligte Einrichtung: CF-Center, Klinikum Westbrandenburg, Campus Brandenburg an der Havel, Germany; Medizinische Hochschule Brandenburg (MHB), Universitätsklinikum, Brand…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Benzodioxoles, Quinolones. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vertex Pharmaceuticals Incorporated.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: Recently, elexacaftor/tezacaftor/ivacaftor (ETI), the turning point in the course of Cystic fibrosis (CF), was also approved for children with CF (cwCF) aged 6-11 years carrying at least one F508del mutation. Modulating the causative deficiency in the CF transmembrane conductance regulator channel was found to substantially improve the crucially affected respiratory and digestive CF-manifestations. In this regard, using the CFAbd-ScoreⒸ, we previously found that ETI decreases significantly abdominal symptoms (AS) in people with CF aged ≥ 12 years. AIMS: Assessing changes in AS after ETI initiation in cwCF aged 6-11 years with the novel pediatric Patient-Reported Outcome-Measure CFAbd-Score.kidⒸ. METHODS: The CFAbd-Score.kidⒸ, specially developed and validated for cwCF aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CF-Center, Klinikum Westbrandenburg, Campus Brandenburg an der Havel, Germany; Medizinische Hochschule Brandenburg (MHB), Universitätsklinikum, Brandenburg an der Havel, Germany. Electronic address: j.mainz@uk-brandenbu…
- CF-Center, Klinikum Westbrandenburg, Campus Brandenburg an der Havel, Germany; Medizinische Hochschule Brandenburg (MHB), Universitätsklinikum, Brandenburg an der Havel, Germany.
- CF-Center, Klinikum Westbrandenburg, Campus Brandenburg an der Havel, Germany; Medizinische Hochschule Brandenburg (MHB), Universitätsklinikum, Brandenburg an der Havel, Germany; Department of Gastroenterology, Brandenb…
- Department of Pediatrics, Justus-Liebig-University, Giessen, Germany.
- Division of Allergy, Pulmonology and Cystic Fibrosis, Department for Children and Adolescents, University Hospital Frankfurt a.M., Goethe University, Germany.
- Children's Hospital, Eberhard-Karls-University, Tübingen, Germany.
Förderung
- Vertex Pharmaceuticals Incorporated
Zitieren
APA
Mainz, J. G., Sadrieh, P., Bechinger, L., Duckstein, F., Barucha, A., Polte, L., Naehrlich, L., Eickmeier, O., van Dullemen, S., Graepler-Mainka, U., & Zagoya, C. (2025). The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first results. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.09.003
Vancouver
Mainz JG, Sadrieh P, Bechinger L, Duckstein F, Barucha A, Polte L, et al. The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first results. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.09.003
BibTeX
@article{Mainz2025,
author = {Mainz, Jochen G and Sadrieh, Pauline and Bechinger, Lilith and Duckstein, Franziska and Barucha, Anton and Polte, Louise and Naehrlich, Lutz and Eickmeier, Olaf and van Dullemen, Suzanne and Graepler-Mainka, Ute and Zagoya, Carlos},
title = {The novel CFAbd-Score.kidⒸ reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on Elexacaftor/Tezacaftor/Ivacaftor – first results},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.09.003}
}
EUVIMED